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Introduction
Metastatic brain tumor occurs ten times more than the primary brain tumors. This happens to 24∼45% of all cancer patients. 1) As life expectancy of cancer patients has increased along with development of chemotherapy, surgery and radiotherapy for treatment of Lung cancer and Breast cancer, the incidence of brain metastases have been increased. 2, 3) In the case of lung cancer or breast cancer which cancer spreads to the brain often, when there are brain metastases with syptoms, the status of patients became terminal. Those patients should be considered for appropriate treatment of radiation therapy or surgery. 4) As life expectancy of cancer patients has increased with development of chemotherapy, surgery and radiotherapy the chance of treatment for metastatic brain tumor has increased as well.
Those patients with neurologic symptom such as headache, visual disturbance, ataxia could be identified with brain CT or brain MRI. Lung cancer or breast cancer has high propensity to spread to the brain. A proper radiotherapy of brain metastases can be a benefit to survival in some patient with palliation of symptoms.
5)
The patient with brain metastases undergo palliative radiotherapy. Of these patients disease progression with neurologic symptom can be included in a second course of irradiation.
Reirradation of brain lesion could be controversy because of treatment related side effects and palliative efficacy [6] [7] [8] [9] [10] .
We analyzed the outcome of reirradiation for cranial metastases patients at our institution to assess appropriate selection of patient with favorable factor. Survival time was defined as time from the start of reirradiation to the date of death using the Kaplan-Meier method.
Statistical analysis was carried out using the log-rank test to test whether there was a difference between the survival times of different group of patients and treatment factors. Extracranial disease status was determined by official radiologic images.
Patients' characteristics are listed in Table 1 .
Treatment
Treatment is listed in Table 2 . Three radiotherapy technique for brain metastases were whole brain radiotherapy (WBRT), (Table 2 ).
Palliative treatment efficacy
Response criteria were defined as follows: relief of symptoms, stable status, aggravation of symtoms. Using the medical records, Karnofsky performance status (KPS) at time prior to reirradiation and KPS after reirradiation were obtained.
Results
The most common technique of RT was whole brain radio- val between the two courses of brain RT was 13.6 months (median, 11.1; range, 1∼38).
The palliative efficacy of symptoms are listed in Table 3 .
Of 23 total patients, 11 (47.8%) patients experienced more than partial resolution of symptoms. 8 patients did not experience any symptom improvement. 4 (17.3%) patients had symptom aggravation.
The performance status was compared before and after reirradiation. At the time prior to brain reirradiation, the mean KPS was 42.2 (median, 30). The mean KPS after irradiation was 52.7 (median, 60). At the 3-month follow-up, 8 patients were deceased with disease progression, and the mean KPS before reirradiation was 32.5 (median, 30) (Fig. 3) . Two patients died of progressive primary disease during the course of reirradiation.
The median overall survival after the reirradiation of brain metastases was 3.2 months (Fig. 1) 19) presented the time interval between two radiation course (≤6 months vs. 6∼11.9 months vs. ≥12 months) did not show any significant differences in survival. The protocol of our institution is to limit the process of brain reirradiation for patients who have at least a 6 month time interval from the completion of the first treatment except a few cases with worsening symptomatic brain metastasis after initial course of RT. This practice is a result of concern for increased risk of neurological toxicities caused by the short time intervals between two consecutive radiation treatments. In our study, one (4.3%) patient had treatment related grade 3 adverse events.
The patient underwent two courses of 3D conformal radiotherapy for partial brain metastasis. Dose for the first course of RT was 30 Gy with a fraction size of 3 Gy, followed by reirradiation course of 25 Gy with a fraction size of 2.5 Gy.
The patient developed grade 3 headache. The cumulative biological equivalent doses (BED) of the patient were 105.8 (α/ β=3 Gy) and 70.2 Gy (α/β=10 Gy). The time interval of two courses was 4 months.
In case of whole brain radiation therapy (WBRT) for purpose of palliation, there is controversy about its safety. Emami et al. 20) reported normal organ tissue tolerance doses in various organs and tissues. These data were applied to a partial dosevolume model, and the TD 5/5 (total radiation dose that can induce 5% of complication within 5 years) of whole brain, 2/3 of brain, and 1/3 of brain were reported as 4,500 cGy, 5,000 cGy, and 6,000 cGy, respectively. More recently, the Quantitative Analysis of Normal Tissue Effects in the Clinic review 21) refined the normal tissue dose volume tolerance guidelines for the brain of modern era radiotherapy. In our study, three patients who underwent repeated whole brain radiotherapy did not tend to have worse survival outcomes or treatment related side effects than other group of treatment options. The patients had more significant disease burden prior to reirradiation. This result of toxicity could be attributed to the fact that patients with limited follow up time because that the patients might be deceased before late toxicity develops. However, Son et al. 12) reported 17 patients who received a repeat course of WBRT with no Grade 3 toxicities. Mayer et al. 11) presented that radiation-induced normal brain tissue necrosis is found to occur at NTDcumulative＞100 Gy. There were no association between the time interval between the initial and reirradiation course and the incidence of radionecrosis.
Prior studies have analyzed correlations between brain reirradiation and historically favorable prognostic factors, including performance status (KPS＞70), absence of extracranial disease, and age. Sadikov et al. 19) found that Eastern Cooperative These patients were RPA class III and had primary disease progressive status. Time interval between two courses of irradiation was not factor of palliative efficacy. We analyzed association of segmented KPS with survival of patients (Fig. 3 ).
There was statistically significant correlation between survival and KPS value of 60 (Fig. 2) . The median overall survival for patient good performance status (KPS≥60: ECOG 0∼2) was 16 months, compared with 3 months for patient with KPS under 60 (p=0.015). In comparison with previous studies, patient population of our study was not quite favorable performance status, with a median initial KPS of 30 and majority of lung cancer patient number than breast cancer. We found that there was a trend for better survival for patients with primary breast cancer and with stable extracranial disease.
Conclusion
Within the limitations of a retrospective review, we found clinical benefit to reirradiation in 82.6% of patients including maintained symptom, and a median survival of 3.2 months in patients who have progressed or relapsed after an initial course of radiation therapy for brain metastases.
This study demonstrated that it may be most useful in patients with a good performance status KPS≥60 (: ECOG 0∼
2) prior to reirradiation and with stable extracranial disease. In our study, even patients with poor prognostic factors experienced the palliation efficacy of reirradiation.
In conclusion, brain reirradiation could be appropriate in symptom palliation efficacy with tolerable toxicity.
